US EditionCentanafadine: New NDSRI Drug for ADHD Targets NorepinephrineFooterLogo
2 Articles
2 Articles
Centanafadine: New NDSRI Drug for ADHD Targets NorepinephrineFooterLogo
June 24, 2025 Centanafadine — a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) — is effective at treating ADHD in adults, adolescents, and children, according to Phase 3 trials sponsored by the drug’s manufacturer, Otsuka Pharmaceuticals. The non-stimulant ADHD medication offers the potential benefits of mild side effects and a low abuse potential, and it works by increasing levels of three different neurotransmitters involve…
Patients in their 40s and 60s account for 60% of all prescription patients… Prescriptions for those under 10 have doubled in the past 5 years. Last year, the number of patients taking narcotics in Korea exceeded 20 million, showing a continuous increase in the number of prescription patients. On the 24th, the Ministry of Food and Drug Safety and the Korea Pharmaceutical Safety Management Agency
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
